{"id":379398,"date":"2020-11-12T07:03:38","date_gmt":"2020-11-12T12:03:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379398"},"modified":"2020-11-12T07:03:38","modified_gmt":"2020-11-12T12:03:38","slug":"valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/","title":{"rendered":"Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>\n          <b>Amikacin receives Health Canada approval, commercialization to start in first half of 2021 <\/b>\n        <\/li>\n<li>\n          <b>Strong start for Ethacrynate Sodium commercialization in the U.S.<\/b>\n        <\/li>\n<li>\n          <b>Heightened commercial and scientific interest in Hesperco\u2122 preceeds retail launch <\/b>\n        <\/li>\n<li>\n          <b>Strong fourth quarter sales growth favourably impacted by recent launches of Yondelis and Ametop<\/b><br \/>\n          <b \/>\n        <\/li>\n<\/ul>\n<p>\n        <span class=\"xn-location\">MONTREAL<\/span>, <span class=\"xn-chron\">Nov. 12, 2020<\/span> \/PRNewswire\/ &#8211; \u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979595-1&amp;h=2116841924&amp;u=https%3A%2F%2Fwww.valeopharma.com%2F&amp;a=Valeo+Pharma+Inc\" rel=\"nofollow noopener noreferrer\">Valeo Pharma Inc<\/a>. (CSE:VPH) (OTCQB: VPHIF) (FRANKFURT: VP2), a Canadian pharmaceutical company,\u00a0 announced today that it has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting. Valeo also announced that shipments of\u00a0 Ethacrynate Sodium have commenced in the U.S. market. \u00a0<\/p>\n<p>&#8220;The approval of Amikacin adds to our portfolio of hospital specialty products, an important and growing part of our revenue stream&#8221;, said <span class=\"xn-person\">Steve Saviuk<\/span>, President and CEO. &#8220;We are also pleased with the commercial uptake of Ethacrynate Sodium, our first product launched in the U.S. market.&#8221;<\/p>\n<p>&#8220;Valeo experienced strong revenue growth in the fourth quarter (ended <span class=\"xn-chron\">October 31<\/span><sup>st<\/sup>) which was aided by the recent launches of Yondelis and Ametop, they combined to contribute 20% of the quarter&#8217;s revenues,&#8221;added Saviuk. &#8220;We look for revenue growth to accelerate in the coming quarters through both organic growth and additional product launches&#8221;.<\/p>\n<p>&#8220;We have also been receiving heightened commercial and scientific interest in Hesperco\u2122, a flavonoid capsule formula that supports the body&#8217;s immune system&#8221;, continued Saviuk. &#8220;Hesperco\u2122 is available online through our <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979595-1&amp;h=4154077682&amp;u=http%3A%2F%2Fwww.hesperco.com%2F&amp;a=www.Hesperco.com\" rel=\"nofollow noopener noreferrer\">www.Hesperco.com<\/a> website and will soon be available through retailers and Amazon in <span class=\"xn-location\">Canada<\/span>. We are proceeding with registration of Hesperco\u2122 in the U.S. and we are actively planning our U.S. logistics and marketing launch.&#8221;<\/p>\n<p>\n        <b>Grant of options<\/b>\n      <\/p>\n<p>The Company also announces that it has granted a total of 260,000 share options under its Share Option Plan to one consultant and one employee of the Company. Additional information concerning these grants can be found in the <i>Form 11 \u2013 Notice of Proposed Stock Options <\/i>posted on the CSE website, under the Company&#8217;s profile. <\/p>\n<p>\n        <b>About Valeo Pharma<\/b>\n      <\/p>\n<p>Valeo Pharma is a Canadian pharmaceutical company dedicated to the in-licensing and commercialization of innovative pharmaceutical products in <span class=\"xn-location\">Canada<\/span> with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in <span class=\"xn-location\">Kirkland, Quebec<\/span> Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit <b><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979595-1&amp;h=159727808&amp;u=http%3A%2F%2Fwww.valeopharma.com%2F&amp;a=www.valeopharma.com\" rel=\"nofollow noopener noreferrer\">www.valeopharma.com<\/a><\/b>and follow us on <b><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979595-1&amp;h=923939478&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fvaleo-pharma&amp;a=LinkedIn\" rel=\"nofollow noopener noreferrer\">LinkedIn<\/a><\/b>\u00a0and <b><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979595-1&amp;h=807756503&amp;u=https%3A%2F%2Ftwitter.com%2Fvaleo_pharma%3Flang%3Den&amp;a=Twitter\" rel=\"nofollow noopener noreferrer\">Twitter<\/a><\/b><b>.<\/b><\/p>\n<p>\n        <b>Forward Looking Statements<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements about Valeo&#8217;s objectives, strategies and businesses that involve risks and uncertainties. These statements are &#8220;forward-looking&#8221; because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.<\/p>\n<p>NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO89489&amp;sd=2020-11-12\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/valeo-pharma-announces-amikacin-approval-in-canada-and-us-launch-of-ethacrynate-sodium-301171555.html\">http:\/\/www.prnewswire.com\/news-releases\/valeo-pharma-announces-amikacin-approval-in-canada-and-us-launch-of-ethacrynate-sodium-301171555.html<\/a><\/p>\n<p>SOURCE  Valeo Pharma Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=MO89489&amp;Transmission_Id=202011120700PR_NEWS_USPR_____MO89489&amp;DateId=20201112\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Amikacin receives Health Canada approval, commercialization to start in first half of 2021 Strong start for Ethacrynate Sodium commercialization in the U.S. Heightened commercial and scientific interest in Hesperco\u2122 preceeds retail launch Strong fourth quarter sales growth favourably impacted by recent launches of Yondelis and Ametop MONTREAL, Nov. 12, 2020 \/PRNewswire\/ &#8211; \u00a0Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FRANKFURT: VP2), a Canadian pharmaceutical company,\u00a0 announced today that it has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting. Valeo also announced that shipments of\u00a0 Ethacrynate Sodium have commenced in the U.S. market. \u00a0 &#8220;The approval of Amikacin adds to our portfolio of hospital specialty products, an &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379398","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Amikacin receives Health Canada approval, commercialization to start in first half of 2021 Strong start for Ethacrynate Sodium commercialization in the U.S. Heightened commercial and scientific interest in Hesperco\u2122 preceeds retail launch Strong fourth quarter sales growth favourably impacted by recent launches of Yondelis and Ametop MONTREAL, Nov. 12, 2020 \/PRNewswire\/ &#8211; \u00a0Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FRANKFURT: VP2), a Canadian pharmaceutical company,\u00a0 announced today that it has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting. Valeo also announced that shipments of\u00a0 Ethacrynate Sodium have commenced in the U.S. market. \u00a0 &#8220;The approval of Amikacin adds to our portfolio of hospital specialty products, an &hellip; Continue reading &quot;Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T12:03:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO89489&amp;sd=2020-11-12\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium\",\"datePublished\":\"2020-11-12T12:03:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/\"},\"wordCount\":536,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO89489&amp;sd=2020-11-12\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/\",\"name\":\"Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO89489&amp;sd=2020-11-12\",\"datePublished\":\"2020-11-12T12:03:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO89489&amp;sd=2020-11-12\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO89489&amp;sd=2020-11-12\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/","og_locale":"en_US","og_type":"article","og_title":"Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium - Market Newsdesk","og_description":"PR Newswire Amikacin receives Health Canada approval, commercialization to start in first half of 2021 Strong start for Ethacrynate Sodium commercialization in the U.S. Heightened commercial and scientific interest in Hesperco\u2122 preceeds retail launch Strong fourth quarter sales growth favourably impacted by recent launches of Yondelis and Ametop MONTREAL, Nov. 12, 2020 \/PRNewswire\/ &#8211; \u00a0Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FRANKFURT: VP2), a Canadian pharmaceutical company,\u00a0 announced today that it has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting. Valeo also announced that shipments of\u00a0 Ethacrynate Sodium have commenced in the U.S. market. \u00a0 &#8220;The approval of Amikacin adds to our portfolio of hospital specialty products, an &hellip; Continue reading \"Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T12:03:38+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO89489&amp;sd=2020-11-12","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium","datePublished":"2020-11-12T12:03:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/"},"wordCount":536,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO89489&amp;sd=2020-11-12","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/","name":"Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO89489&amp;sd=2020-11-12","datePublished":"2020-11-12T12:03:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO89489&amp;sd=2020-11-12","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO89489&amp;sd=2020-11-12"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-amikacin-approval-in-canada-and-u-s-launch-of-ethacrynate-sodium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379398"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379398\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}